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Emerging evidence indicates that prostatic inﬂammation may contribute to prostatic growth in benign
prostatic hyperplasia (BPH) and neoplastic changes (prostate cancer). The Medical Therapy of Prostatic
Symptoms study showed that men with inﬂammation had a signiﬁcantly higher risk of BPH progression
and acute urinary retention. Evidence also shows that a cyclooxygenase-2 (COX-2) inhibitor can increase
apoptotic activity in human BPH tissue. COX-2 inhibitors in combination with alpha-adrenergic blockers
may increase the effectiveness of therapy for lower urinary tract symptoms (LUTS) secondary to BPH
without signiﬁcant side effects. COX-2 inhibitors may decrease the serum prostatic-speciﬁc antigen level
and act as a biomarker to differentiate chronic inﬂammation from prostate cancer in patients with LUTS
suggestive of BPH who do not have a palpable prostate nodule but have a serum prostatic-speciﬁc
antigen level higher than 4 ng/mL. The results might provide a simple way to initially differentiate
chronic inﬂammation from prostatic cancer. If chronic inﬂammation of the prostate can be reduced by
COX-2 inhibitor treatment, bothersome LUTS as well as voiding conditions might be improved.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Lower urinary tract symptoms and inﬂammation
Lower urinary tract symptoms (LUTS) are commonly divided
into storage, voiding, and postmicturition symptoms. Male LUTS
are historically linked to benign prostatic hyperplasia (BPH) but are
not necessarily prostate related. Women and children may also
have LUTS. LUTS include symptoms of overactive bladder (OAB),
which are often associatedwith detrusor overactivity and increased
bladder sensation. Recent studies revealed that chronic inﬂam-
mation of the urinary tract could be an etiology for LUTS inmen and
women. Elevated levels of urinary nerve growth factor as well as
C-reactive protein have been reported in patients with OAB and in
men with BPH [1,2].
Treatment for male LUTS/BPH has traditionally involved the use
of alpha-1 adrenoceptor antagonists (alpha-blockers) and 5-alpha-
reductase inhibitors with satisfactory results. However, some
patients still do not beneﬁt from these treatments. Adding anti-
muscarinic agents has been shown to have beneﬁcial effects onBuddhist Tzu Chi General
, Taiwan. Tel.: þ886 3 856
ddhist Compassion Relief Tzu ChiLUTS/BPH refractory to alpha-blocker therapy [3]. Bladder
dysfunction is likely to be the cause of symptoms in this subgroup
of patients [4].
A retrospective study reviewing all histopathological examina-
tions of BPH in patients undergoing transurethral resection of the
prostate showed that chronic inﬂammation was present in 43.1% of
prostate specimens. Chronic inﬂammationwas noted in association
with BPH in 43.1% of cases. There was a signiﬁcant trend to increase
with age decades for high-grade prostatic intraepithelial neoplasia.
A signiﬁcant difference was found in incidental prostate carcinoma
(IC, T1a, and T1b) distribution in the different decades of age; and
especially in regards to both T1a and T1b tumors, there was a trend
to increase with patient age. Different histological variables asso-
ciated to BPH are differently inﬂuenced by the age of patients and
prostate volume, and they differently inﬂuence serum prostatic-
speciﬁc antigen (PSA) levels [5].
2. Cyclooxygenase-2 inhibitor effects on LUTS and prostate
disease
Emerging evidence indicates that prostatic inﬂammation may
contribute to prostatic growth in BPH and neoplastic changes
(prostate cancer). The Medical Therapy of Prostatic SymptomsFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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higher risk of BPH progression and acute urinary retention [6].
Evidence also shows that a cyclooxygenase-2 (COX-2) inhibitor can
increase apoptotic activity in human BPH tissue. Analyses of
bacterial colonization in prostate cancer and normal prostate tissue
showed a highly suggestive correlation between bacterial coloni-
zation/chronic inﬂammation and the diagnosis of prostate cancer
[7]. Evidence from genetic studies supports the hypothesis that
prostate inﬂammation may be a cause of prostate cancer devel-
opment. Proliferative inﬂammatory atrophy has been considered as
an early histologic precursor to prostatic intraepithelial neoplasia
and prostate cancer. The concept that inﬂammation can promote
chronic prostatic diseases, such as BPH or prostate cancer, is actu-
ally supported by several new signiﬁcant ﬁndings [8].
COX-2 is expressed in human BPH tissue and displays either
a proinﬂammatory effect or a proliferative effect on prostate cells.
In a single-center unblinded trial, 46 consecutive men with LUTS
and BPH were randomized to receive rofecoxib 25 mg/d plus
ﬁnasteride 5 mg/d (Group B) versus ﬁnasteride 5 mg/d alone
(Group A) for 24weeks. The advantages of the combination therapy
compared with ﬁnasteride alone were signiﬁcant after a short time
(4 weeks). It can be hypothesized that the association of rofecoxib
with ﬁnasteride induces a more rapid improvement in clinical
results until the effect of ﬁnasteride becomes predominant [9].
Fifty-sevenpatients complaining of LUTS secondary to BPHwere
randomly assigned to receive doxazosin 4 mg or doxazosin 4 mg
plus tenoxicam 20 mg. The total International Prostate Symptom
Score, International Prostate Symptom Score quality-of-life index,
and Overactive Bladder Symptom Score decreased signiﬁcantly in
both groups compared with baseline (p< 0.01). The improvements
in these parameters were signiﬁcantly better in patients treated
with combination therapy (p< 0.05) [10]. COX-2 inhibitors in
combination with alpha-blockers may increase the effectiveness of
therapy for LUTS secondary to BPH without signiﬁcant side effects.
Nocturia is a well-recognized symptom of BPH and is commonly
treated by alpha-blockers and/or 5-alpha-reductase inhibitors.
However, the effectiveness of these drugs for nocturia has been
reported to be only 25%e39%. Intravesical instillation with COX-2
inhibitors can reduce cyclophosphamide-induced bladder hyper-
activity and expression of inducible notric oxide synthase and
nerve growth factor. Intravesical instillation with COX-2 inhibitors
can be considered a possible treatment for OAB [11]. One recent
clinical study investigated the efﬁcacy of celecoxib, a COX-2
inhibitor, in the treatment of patients with BPH complaining of
nocturia. The results showed that celecoxib is effective in the
treatment of patients with BPH complaining of refractory nocturia
and suggested that this is a novel treatment option for this common
condition [12].
3. COX-2 inhibitor effects on PSA and prostatic disease
PSA is a sensitive biomarker for prostate cancer. However, serum
PSA level also increase in patients with large BPH and acute and
chronic prostatitis. Urologists usually recommend a prostatic
biopsy for patients with an elevated serum PSA. The positive biopsy
ratewas 22% and 10% for the ﬁrst and repeat biopsy in patients with
suspected prostate cancer. Immediate morbidity included rectal
bleeding (2.1%), mild hematuria (62%), severe hematuria (0.7%), and
moderate-to-severe vasovagal episodes (2.8%). Delayed morbidity
comprised fever (2.9%), hematospermia (9.8%), recurrent mild
hematuria (15.9%), persistent dysuria (7.2%), and urinary tractinfection (10.9%) [13]. If we can use pharmacological manipulation
and adequately treat chronic inﬂammation in patients with LUTS/
BPH and elevated PSA levels, prostatic biopsy could be avoided in
some patients and the complication rate might be reduced.4. Hypothesis
Chronic inﬂammation has been considered a possible but
important factor inducing LUTS and promoting prostatic growth.
PSA elevation is a sensitive but not speciﬁc sign of prostatic cancer.
To reduce the need for prostatic biopsy in patients with an elevated
serum PSA level, it is mandatory to ﬁnd a simple method for initial
differentiation of chronic inﬂammation from prostatic cancer. We
hypothesize that COX-2 inhibitors might decrease serum PSA levels
and act as a tool to differentiate chronic inﬂammation from pros-
tate cancer in patients with LUTS/BPH who do not have a palpable
prostate nodule but have a serum PSA level higher than 4 ng/mL.
If serum PSA can be reduced signiﬁcantly after celecoxib therapy
and the positive rate following prostatic biopsy is lower than that in
patients without a reduced PSA after celecoxib treatment, wemight
use COX-2 inhibitor treatment for the initial management of an
elevated PSA level in men with LUTS/BPH who do not have
a palpable nodule. Furthermore, if chronic inﬂammation of the
prostate can be reduced, bothersome LUTS and voiding conditions
might be improved. This can be another beneﬁt for men with LUTS
who are worried about surgical intervention.References
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